TY - JOUR
TI - Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis
AU - Pitsios, C.
AU - Papadopoulos, D.
AU - Kompoti, E.
AU - Manoussakis, E.
AU - Garris, V.
AU - Petalas, K.
AU - Tassios, I.
AU - Baibas, N.
AU - Kontou-Fili, K.
AU - Saxoni-Papageorgiou, P.
AU - Papadopoulos, N.G.
JO - Annals of Allergy, Asthma and Immunology
PY - 2006
VL - 96
TODO - 5
SP - 673-678
PB - American College of Allergy, Asthma and Immunology
SN - null
TODO - 10.1016/S1081-1206(10)61064-2
TODO - mometasone furoate;  nedocromil sodium, adolescent;  adult;  application site burning;  article;  clinical trial;  controlled clinical trial;  controlled study;  disease severity;  drug efficacy;  drug safety;  epistaxis;  female;  fever;  grass pollen;  hay fever;  headache;  human;  insomnia;  major clinical study;  male;  olive;  open study;  Parietaria;  patient satisfaction;  pollen allergy;  priority journal;  prophylaxis;  randomized controlled trial;  school child;  somnolence;  taste disorder
TODO - Background: The preventive use of medications has been proposed to be effective in the treatment of seasonal rhinitis. Objective: To evaluate the efficacy and safety of mometasone furoate and nedocromil sodium nasal sprays as prophylactic treatment for moderate to severe seasonal allergic rhinitis (SAR). Patients: Sixty-one patients were recruited from 3 referral allergy centers. Inclusion criteria were history of SAR for 2 years or longer, sensitization to relevant local pollen (grasses, Parietaria, and olive), and age older than 12 years. Methods: An open-label, randomized, parallel-group, "real-life" study design was used. Patients received mometasone furoate nasal spray once daily or nedocromil sodium nasal spray 3 times daily starting 2 to 4 weeks before the pollen season and continuing for up to 4 months. Instructions regarding the use of additional medications were given. Diary cards recording symptoms, use of medication, and adverse events were kept by the patients. Results: All 61 patients completed the study. The prophylactic use of mometasone furoate vs nedocromil sodium led to significantly more days without symptoms (75.1% vs 54.5%; P < .001). The mometasone furoate group also had lower nasal symptom scores (mean, 1.4 vs 2.9; median, 0 vs 2; P < .001) and was more satisfied (93.1% vs 43.5%; P < .001). No serious adverse event was recorded, and there was no difference between the treatments in any adverse event. Conclusions: Prophylactic administration of mometasone furoate before the pollen season is safe and may lead to improved control of SAR compared with the use of nedocromil sodium.
ER -